Eye Cancer

Furthermore, the anti-tumor effect of CM-Thy was validated through various mechanisms involved in tumor formation such as angiogenesis and vasculogenic mimicry. Interestingly, the results from visible light experiments conducted in vitro also substantiated the remarkable therapeutic efficacy of this system for refractive eye disorders while providing innovative ideas for cross-species biological interventions.

Although agents such as lenalidomide and Bruton's tyrosine kinase(BTK) inhibitors have demonstrated efficacy in relapsed/refractory (R/R)PVRL, their role in treatment-naïve patients remains unclear. In conclusion, the combination of Orelabrutinib, rituximab, and intravitreal MTX is a feasible therapeutic strategy for PVRL. Our findings may contribute to a potential paradigm shift in the management of this rare disease.

Additionally, we discuss its interactions with autophagy, cellular senescence, and cell death, exploring its potential as a therapeutic target in inflammatory and neoplastic eye conditions. Finally, we identify key unresolved questions and outline future research directions aimed at exploiting cGAS-STING modulation for precision therapies in vision-threatening diseases.

Permanent pathway activation by Rb deletion initiated continuous stem cell division. Thus, beyond their classical hormonal roles in physiology, growth, and aging, Igf proteins operate locally and rapidly with Igfbp and Rb to control injury-induced stem cell proliferation and tumor initiation.

P1, N=36, Not yet recruiting, Aura Biosciences, Inc.

Due to the rarity of the condition, evidence for the optimal diagnostic approach and management is limited. Therefore, this case provides an insight into our approach, using the recently published European Haematology Association-European Society for Medical Oncology clinical practice guideline for primary central nervous system lymphoma, along with our recommendations on strategies to facilitate earlier diagnosis and treatment.

P=N/A, N=500, Active, not recruiting, Leiden University Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2030 --> Apr 2031 | Trial primary completion date: Sep 2025 --> Apr 2028

P=N/A, N=150, Not yet recruiting, Assiut University

Our findings reveal a distinct proteomic signature in epithelioid UM characterized by dedifferentiation and enhanced mitochondrial respiration. This study provides the first regionally resolved proteomic landscape of UM pathology and suggests that the epithelioid transformation may reflect a shift toward a dedifferentiated, metabolically active tumor state.

Pathway analysis revealed activation of inflammatory and tumor microenvironment pathways, and upstream regulator analysis identified VEGFA and CCL2 as potential drivers. These findings demonstrate that calibrated AH proteomic profiling can identify clinically measurable protein changes associated with UM risk and stage, supporting its potential utility for biomarker development.

Overall, our results suggest that DHA suppresses UM progression by inducing ferroptosis and mitochondrial dysfunction, while the HO-1 and xCT/GPX4 pathways may contribute to these effects. DHA may represent a potential therapeutic approach for UM, warranting further investigation.